CLINICAL TRIALS PROFILE FOR GIAPREZA
✉ Email this page to a colleague
All Clinical Trials for GIAPREZA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03431077 ↗ | A Study of LJPC-501 in Pediatric Patients With Hypotension | Completed | La Jolla Pharmaceutical Company | Phase 2 | 2018-02-11 | The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) or reduction in sum norepinephrine (NE) equivalent dosing, at Hour 2 after the start of LJPC-501, in pediatric patients who remain hypotensive despite receiving fluid therapy and vasopressor therapy. In addition, this study will evaluate the safety and tolerability of LJPC-501 in pediatric patients, the change in MAP over 24 hours after the start of LJPC-501, the change in serum lactate concentrations, and the change in Pediatric Logistic Organ Dysfunction (PELOD) scores. |
| NCT03733145 ↗ | Angiotensin II in General Anesthesia | Recruiting | La Jolla Pharmaceutical Company | Phase 1 | 2019-10-03 | Hypotension in adult patients undergoing general anesthesia is common. This can lead to hypoperfusion of vital organs, organ damage, and states of increased metabolic duress. This may be worse in patients with underlying essential hypertension and worse in patients taking Angiotensin Converting Enzyme Inhibitors (ACE) and Angiotensin Receptor Blockers (ARBs). Intravenous (IV) administration of Ang II may be an effective treatment of hypotension in this patient population. |
| NCT03733145 ↗ | Angiotensin II in General Anesthesia | Recruiting | Wake Forest University Health Sciences | Phase 1 | 2019-10-03 | Hypotension in adult patients undergoing general anesthesia is common. This can lead to hypoperfusion of vital organs, organ damage, and states of increased metabolic duress. This may be worse in patients with underlying essential hypertension and worse in patients taking Angiotensin Converting Enzyme Inhibitors (ACE) and Angiotensin Receptor Blockers (ARBs). Intravenous (IV) administration of Ang II may be an effective treatment of hypotension in this patient population. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GIAPREZA
Condition Name
Clinical Trial Locations for GIAPREZA
Trials by Country
Clinical Trial Progress for GIAPREZA
Clinical Trial Phase
Clinical Trial Sponsors for GIAPREZA
Sponsor Name
